Quince Therapeutics, Inc. — Form 8-K/A
Filed July 30, 2026 · analyzed by the 8-K Agent
8-K/A
▲ Likely positive
significance 72/100
What the filing says
On May 18, 2026, Quince Therapeutics completed acquisition of Orphai Therapeutics for an undisclosed upfront amount. Quince received $115 million gross upfront proceeds in a private placement from a 13-member investor syndicate led by Balyasny, Affinity, Coastlands, and others. Up to $72 million additional warrant exercise proceeds are available, plus $11 million to former Orphai shareholders. LAM-001 (inhaled rapamycin dry powder) is Quince's lead asset: Phase 2a in PH-ILD/PAH completed (10 patients, 6 completed); Phase 2b ongoing in PH-ILD (75 patients, Q1 2028 data); Phase 2 in BOS ongoing (19 patients, fully enrolled, Q1 2027 data); Phase 2 SAPH planned (late 2026, Q4 2028 data). Orphan drug designations granted for BOS, PAH, LAM, sarcoidosis (US) and BOS, LAM (EU).
Why this rating
Transformational acquisition of pipeline asset + $115M fundraise is 180% of company's $64M market cap, materially expands scope. Significant relative to size but execution risk remains high.
See more from July 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.